MarketFriction

Torrent Pharmaceuticals Ltd

NSE TORNTPHARM · BSE 500420 · Pharmaceuticals
₹4,767.30 -0.68%
NSE close2026-10-01
52 week range3,480.60 - 5,250.00
Market cap₹1,86,152 Cr.
P/E83.4
Nifty Next 50Nifty 100Nifty 200Nifty 500Nifty PharmaNifty Healthcare IndexNifty India Consumption No price band Delivery 57.2%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales2,6602,7322,7452,8592,8892,8092,9593,1783,3023,3034,1974,921
Expenses1,8351,8631,8621,9551,9501,8951,9952,1462,2192,2152,8413,257
Operating Profit8258698839049399149641,0321,0831,0881,3561,664
OPM %31%32%32%32%32%33%33%32%33%33%32%34%
Other Income26553124-1633-42-37-40-23-83-33
Interest91808075645756564845236305
Depreciation201213203197198199201201204206508593
Profit before tax559631631656661691665738791814529733
Tax %31%30%29%30%31%27%25%26%25%22%31%23%
Net Profit386443449457453503498548591635364566
EPS in Rs11.4113.0913.2713.5013.3814.8614.7116.1917.4618.7610.7616.72
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales6,6875,8165,9507,6737,9398,0058,5089,62010,72811,51613,98015,723
Expenses3,9544,4384,6015,6905,7695,5246,0776,7787,3607,7959,42110,532
Operating Profit2,7331,3771,3491,9832,1702,4802,4312,8423,3683,7214,5585,191
OPM %41%24%23%26%27%31%29%30%31%32%33%33%
Other Income32223299-30012157-28845146-1-182-179
Interest184206308504451353255333354252385634
Depreciation2383074096186546586627078087951,1191,511
Profit before tax2,3431,0889315621,1871,5261,2261,8472,3522,6732,8722,867
Tax %26%14%27%22%14%18%37%33%30%28%26%
Net Profit1,7339346784361,0251,2527771,2451,6561,9112,1382,156
EPS in Rs51.2227.5920.0412.8930.2836.9922.9736.7948.9456.4763.9263.70
Dividend Payout %34%25%35%66%53%47%105%60%57%57%59%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth8%12%13%33%
Compounded Profit Growth2%12%22%10%
Stock Price CAGR20%26%36%36%
Return on Equity22%24%26%27%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital8585858585858585169169169169
Reserves2,4063,4094,2664,5384,6404,7395,7535,8686,0296,6877,4218,219
Borrowings2,7402,3522,5106,4626,0385,7844,8744,0705,3694,0223,20215,026
Other Liabilities2,5893,0402,7403,1593,3513,4023,3632,8843,0433,6273,60320,200
Total Liabilities7,8208,8869,60114,24314,11314,01014,07512,90614,61014,50514,39643,614
Fixed Assets2,8332,8593,6887,8557,7487,5337,0656,4238,1218,1387,94733,191
CWIP6781,042519647617712889630765361478641
Investments2987808044923532181226199173156948
Other Assets4,0114,2064,5895,2495,3955,7635,9405,6285,5245,8345,8158,833
Total Assets7,8208,8869,60114,24314,11314,01014,07512,90614,61014,50514,39643,614
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity8102,7421,0098941,7981,3932,0051,8032,3683,2662,5853,023
Cash from Investing Activity-2,113-869-798-4,677-246229-444-196-2,335-160-549-12,630
Cash from Financing Activity1,212-1,435-1933,417-1,314-1,549-1,651-1,78177-2,780-2,29810,151
Net Cash Flow-9043718-36623873-89-174110327-262544
Free Cash Flow5742,1505231051,1389901,6711,6071,9532,9671,9912,386
CFO/OP85%121%101%87%105%77%88%91%97%112%86%84%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1257960776876697074635979
Inventory Days275314318429318362456368298310334338
Days Payable472523356447345345351250224284239254
Cash Conversion Cycle-71-1302159429317418814789154163
Working Capital Days29-128-80-62-52-57-33-277-26
ROCE %27%48%19%13%13%15%17%19%20%23%27%15%
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Jul 2026
Promoters71.25%71.25%71.25%71.25%68.31%68.31%68.31%68.31%68.31%68.31%68.31%60.78%
FIIs14.08%14.14%14.22%14.46%16.17%16.31%16.09%15.92%16.13%16.18%15.44%17.97%
DIIs7.11%7.15%7.17%6.98%8.25%8.25%8.54%9.17%9.05%8.96%9.73%12.77%
Government0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.00%0.10%0.09%
Public7.46%7.34%7.25%7.21%7.17%7.02%6.93%6.47%6.41%6.55%6.42%8.39%
No. of Shareholders69,11771,15474,76579,84885,03586,00581,85678,22676,21483,81185,7761,40,599

Fundamentals

Market Cap₹ 1,86,152 Cr.
Current Price₹ 4,894
Stock P/E83.4
Book Value₹ 248
ROCE15.2 %
ROE27.4 %
Dividend Yield0.78 %
Face Value₹ 5.00
Compounded Sales Growth (TTM)33%
Compounded Profit Growth (TTM)10%
Consolidated figures.
Valuation
Market capRs 161,347 Cr
Enterprise valueRs 175,207 Cr
P/E (TTM)74.84x
Price to book19.23x
Price to sales10.26x
EV / EBITDA34.96x
EV / EBIT50.05x
EV / sales11.14x
Price to cash flow53.38x
Earnings yield1.34%
Dividend yield0.80%
P/E, 3-year average58.77x
P/B, 3-year average14.75x
P/E, 5-year average49.70x
P/B, 5-year average11.32x
Profitability
Operating margin (excl. other income)32.61%
Operating margin (incl. other income)31.30%
EBITDA margin31.88%
Pre-tax margin18.23%
Net profit margin13.71%
Net margin, latest quarter11.50%
ROE27.08%
ROCE19.04%
ROA7.46%
ROE, 3-year average26.30%
ROCE, 3-year average23.38%
ROA, 3-year average10.69%
ROE, 5-year average22.52%
ROCE, 5-year average20.93%
ROA, 5-year average9.38%
ROIC (approx.)11.71%
Tax rate25.56%
Other income / net worth-2.17%
Growth
Sales growth (latest year)21.39%
Profit growth (latest year)13.19%
Sales CAGR, 3 years13.27%
Sales CAGR, 5 years11.80%
Profit CAGR, 3 years20.22%
Profit CAGR, 5 years11.56%
Sales growth QoQ17.25%
Profit growth QoQ55.49%
Sales growth YoY (latest quarter)54.85%
Profit growth YoY (latest quarter)3.28%
Per share
EPS (TTM)Rs 63.70
EPS (latest year)Rs 63.92
EPS (latest quarter)Rs 16.72
EPS, 3-year averageRs 56.44
EPS, 5-year averageRs 50.41
Book value per shareRs 247.85
Sales per shareRs 464.57
Cash flow per shareRs 89.31
Free cash flow per shareRs 70.50
Dividend per share (latest year)Rs 38.00
Dividend per share, 3-year averageRs 32.67
Dividend per share, 5-year averageRs 33.60
Dividends
Dividend payout59.45%
Dividend payout, 3-year average57.78%
Dividend payout, 5-year average67.53%
Efficiency
Asset turnover0.32x
Fixed asset turnover0.42x
Inventory turnover1.22x
Inventory days300 days
Debtor days79 days
Debtors turnover4.61x
Creditor days254 days
Cash conversion cycle163 days
Working capital days-26 days
Leverage
Total debtRs 15,026 Cr
Cash and bankRs 1,165 Cr
Net debtRs 13,860 Cr
Debt to equity1.79x
Net debt / EBITDA2.77x
Interest coverage5.52x
Current ratio (filing 2026-03-31)1.13x
Quick ratio (filing 2026-03-31)0.75x
Trade payables (filing 2026-03-31)Rs 2,358 Cr
Owners' fund to total sources19.23%
Debt to assets34.45%
Cash flow
Cash from Operating Activity (latest year)Rs 3,023 Cr
Cash from Investing Activity (latest year)Rs -12,630 Cr
Cash from Financing Activity (latest year)Rs 10,151 Cr
Net Cash Flow (latest year)Rs 544 Cr
Free cash flow (latest year)Rs 2,386 Cr
FCFE (approx.: FCF + change in debt)Rs 14,209 Cr
Cash from ops / profit, 5 years1.69x
Sales to cash flow4.62x
Statement figures
Net sales (TTM)Rs 15,723 Cr
Net sales (latest year)Rs 13,980 Cr
Sales (latest quarter)Rs 4,921 Cr
Operating profit excl. other income (latest year)Rs 4,558 Cr
Operating profit (latest quarter)Rs 1,664 Cr
Other income (TTM)Rs -179 Cr
EBITDA (TTM)Rs 5,012 Cr
PBDT (TTM)Rs 4,378 Cr
Profit before tax (TTM)Rs 2,867 Cr
Tax (latest year)Rs 734 Cr
Net profit (TTM)Rs 2,156 Cr
Net profit (latest year)Rs 2,163 Cr
Net profit (latest quarter)Rs 566 Cr
Depreciation (TTM)Rs 1,511 Cr
Depreciation (latest quarter)Rs 593 Cr
Interest (TTM)Rs 634 Cr
Cost of goods sold (latest year)Rs 3,822 Cr
Total expenditure (latest year)Rs 9,421 Cr
Total income (latest year)Rs 13,797 Cr
Share capitalRs 169 Cr
ReservesRs 8,219 Cr
Shareholders' fundsRs 8,388 Cr
Total assetsRs 43,614 Cr
Net blockRs 33,191 Cr
Capital work in progressRs 641 Cr
InvestmentsRs 948 Cr
ReceivablesRs 3,031 Cr
InventoryRs 3,138 Cr
Other liabilitiesRs 20,200 Cr
Shares outstanding (crore)33.84
Ownership
Promoter holding60.78% (-7.53 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 74.8 is at the 91th percentile of its own 9.4-year range (median 57.8, low 21.8, high 91.6).
P/B 19.23 is at the 95th percentile (median 8.93).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodTORNTPHARMNifty 50Difference
1 week-3.3%-2.8% -0.5 pts
1 month-4.0%-6.8% +2.8 pts
3 months-0.0%-7.6% +7.6 pts
6 months+13.0%+0.4% +12.6 pts
1 year+35.0%-9.9% +44.9 pts
2 years+37.9%-13.6% +51.4 pts
3 years+147.1%+14.2% +133.0 pts
5 years+209.5%+27.9% +181.6 pts
341 mutual fund schemes hold about ₹15,873 Cr. Over three months 282 bought more and 28 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
HDFC Large Cap Fund4.04%1,611 +7%
Kotak Mid Cap Fund1.23%876 +100%
Axis Small Cap Fund2.39%753 +100%
Axis Large Cap Fund1.26%397 +20%
UTI Flexi Cap Fund1.43%346 +2%
Axis ELSS-Tax Saver Fund1.00%328 +147%
Kotak Arbitrage Fund(M0.43%323 +180%
Franklin India Large Cap Fund3.99%299 +159%
ICICI Pru Nifty Next 50 Index Fund2.92%296 +48%
SBI Healthcare Opp Fund4.72%274 +42%
Nippon India Small Cap Fund0.31%256 +100%
Mirae Asset Healthcare Fund7.06%251 +1444%
Axis Midcap Fund0.72%247 +100%
UTI Nifty200 Momentum 30 Index Fund2.83%239 +8%
Canara Rob Small Cap Fund1.52%223 +100%
UTI Nifty Next 50 Index Fund2.93%221 +48%
Canara Rob Large Cap Fund1.20%206 +26%
Canara Rob Flexi Cap Fund1.37%188 +100%
Mahindra Manulife Multi Cap Fund2.41%185 +100%
Kotak Large Cap Fund1.63%178 +1%
ICICI Pru Balanced Advantage Fund(M0.23%176 +100%
HDFC Large & Mid Cap Fund0.56%171 +6%
Axis Multicap Fund1.51%166 +137%
Invesco India Contra Fund0.75%155 +100%
Helios Flexi Cap Fund1.74%152 +11%

Red flags

F-score 5 of 8
explainReceivables outrunning sales Receivables grew 62% vs sales +21% in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2024-11-27Jinesh Shah, Designated Person (inOtherother930,144Gift
2021-06-24Shailesh HaribhaktiDirectorbuy6,875Rs 1.99 CrMarket Purchase
2021-06-09Shailesh HaribhaktiDirectorother3,600Rs 1.01 CrPledge Creation
2021-06-02Shailesh HaribhaktiDirectorbuy1,050Rs 0.29 CrMarket Purchase
2021-06-01Shailesh HaribhaktiDirectorbuy1,820Rs 0.50 CrMarket Purchase
2021-05-31Shailesh HaribhaktiDirectorbuy730Rs 0.20 CrMarket Purchase
2020-12-16Harish Guttikar-sell200Rs 0.06 CrMarket Sale
2020-10-20Harish Guttikar-buy400Rs 0.11 CrMarket Purchase
2020-03-31Karan ShahEmployees/Designated Employesell1,085Rs 0.23 CrMarket Sale
2020-03-31Karan ShahEmployees/Designated Employesell117Rs 0.03 CrMarket Sale
2020-03-31Karan ShahEmployees/Designated Employebuy1,085Rs 0.23 CrMarket Purchase
2020-03-31Karan ShahEmployees/Designated Employebuy117Rs 0.03 CrMarket Purchase
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹4,921 Cr +54.8% vs Jun 2025. Net profit ₹566 Cr +3.3%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
Ipca Laboratories Ltd49,17035.817.0 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-05-29Dividend - Rs 9 Per Share
2026-02-18Interim Dividend - Rs 29 Per Share
2025-06-20Dividend - Rs 6 Per Share
2025-01-31Interim Dividend - Rs 26 Per Sh
2024-06-21Dividend - Rs 6 Per Share
2024-02-12Interim Dividend - Rs 22 Per Share
2023-06-23Dividend - Rs 8 Per Share
2023-02-03Interim Dividend - Rs 14 Per Share
2022-07-08Bonus 1:10.5000
2022-02-02Interim Dividend - Rs 25 Per Share
2021-06-17 Dividend - Rs 15 Per Share
2021-02-15 Interim Dividend - Rs 20 Per Share
2020-03-18 Interim Dividend - Rs 17 Per Share Special Dividend - Rs 15 Per Share
2019-06-13 Dividend Rs 4 Per Share
2019-02-06 Interim Dividend - Rs 13 Per Share
2018-06-18 Dividend- Rs 5 Per Share
2018-02-15 Interim Dividend Rs 9/- Per Share (Purpose Revised)
2017-06-19 Dividend - Rs 4/- Per Share
2017-02-10 Interim Dividend Rs 10/- Per Share (Purpose Revised)
2016-03-16 Interim Dividend - Rs 15/- Per Share (Purpose Revised)
2016-02-11 Interim Dividend - Rs 20/- Per Share (Purpose Revised)
2015-06-15Dividend - Rs 6.25/- Per Share
2015-02-02Interim Dividend - Rs 5/- Per Share (Purpose Revised)
2014-06-16Annual General Meeting And Final Dividend Rs.5/- Per Share
2014-01-24Interim Dividend - Rs 5/- Per Share (Purpose Revised)
2013-07-23Bonus 1:10.5000
2013-06-10Final Dividend Rs.7/- Per Share And Special Dividend Rs.10/- Per Share
2013-02-01Interim Dividend Rs 6 Per Share (Purpose Revised)
2012-06-11Annual General Meeting/Dividend Rs 2.50 Per Share
2012-01-27Interim Dividend Rs.6/- Per Share (Purpose Revised)
2011-06-06Final Dividend Rs.6/- Per Share And Special Dividend Rs.2/- Per Share (Purpose Revised)
2010-06-04Dividend-Rs.6/- Per Share
2009-06-08Dividend-Rs.4/-Per Share
2008-06-19Dividend-Rs.3.50/- Per Sh
2007-06-15Agm
2007-03-23Int Div-Rs.3/- Per Share Purpose Revised
2006-06-15Dividend-Rs.2.50/- Per Sh
2006-02-20Inferred from price: close fell to 0.246x overnight, no NSE action on record0.2500
DateTypeWhat it says
2026-09-28AcquisitionAcquisition - Disclosure pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ...
2026-09-10Concall / analyst meetSchedule of meet
2026-09-07Shareholder meetingTorrent Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot
2026-08-11Concall / analyst meetSchedule of meet
2026-08-11General UpdatesGeneral Updates
2026-08-05Shareholder meetingNotice of Postal Ballot
2026-08-04Concall / analyst meetTranscript
2026-08-01Director changeChange in Director(s) of the company.
2026-07-30Concall / analyst meetLink of Recording
2026-07-30Change in ManagementChange in Management
2026-07-30Press ReleaseA press release dated July 30, 2026, titled "A Press Release on Financial Results which is being submitted to the media is also enclosedherewith as an...
2026-07-30Board meeting outcomeUnaudited Financial Results for quarter ended 30-Jun-26
2026-07-28AppointmentAppointment of Shanti Ekambaram as Independent Director of the company w.e.f. July 30, 2026.
2026-07-27General UpdatesGeneral Updates
2026-07-20General UpdatesGeneral Updates - Allotment of 4,19,22,416 fully paid-up Equity shares of the Company to the eligible shareholders of J. B. Chemicals & Pharmaceutical...
2026-07-17General UpdatesGeneral Updates
2026-07-17General UpdatesGeneral Updates
2026-07-17Concall / analyst meetSchedule of meet
2026-07-09Press ReleaseA press release dated July 09, 2026, titled "Semalix Injection Disposable Pens Update".
2026-07-08Amendment to AOA/MOAThe Amendment to AOA/MOA of the company.
2026-07-08General UpdatesGeneral Updates
2026-07-07Record DateRecord date for the purpose of OT is 17-Jul-2026.
2026-07-07General UpdatesGeneral Updates
2026-07-06General UpdatesGeneral Updates
2026-06-23Shareholder meetingTorrent Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on Jun 23, 2026
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
Put / call open interest0.80
Max pain (expiry 2026-10-27)4,800
Largest call open interest at5,000
Largest put open interest at4,500
Implied volatility, at the money21.6%
Underlying at snapshot4,767.30
Open interest by strike around the price, nearest expiry. End-of-day NSE snapshot, 01-Oct-2026 15:40:00. Max pain is the strike where option buyers together would lose the most at expiry.
Trade dateShares sold short
2026-09-29695
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)

Quick answers

What is the market cap of Torrent Pharmaceuticals Ltd?

Torrent Pharmaceuticals Ltd (TORNTPHARM) has a market capitalisation of Rs 1,86,152 Cr. at the 2026-10-01 close.

What is the P/E ratio of Torrent Pharmaceuticals Ltd?

Torrent Pharmaceuticals Ltd trades at a P/E of 83.4 on trailing twelve-month profit, at the 2026-10-01 close.

What were Torrent Pharmaceuticals Ltd's latest quarterly results?

In the Jun 2026 quarter, Torrent Pharmaceuticals Ltd sales was Rs 4,921 Cr (+54.8% vs Jun 2025) and net profit was Rs 566 Cr.

What is the 52-week high and low of Torrent Pharmaceuticals Ltd?

The 52-week high is Rs 5,250.00 and the 52-week low is Rs 3,480.60.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03